Day: June 25, 2023

Fabrice Brégier is appointed Chairman of SCOR’s Board of Directors

Fabrice Brégier is appointed Chairman of SCOR’s Board of Directors

Written by Customer Service on . Posted in Public Companies.

Press ReleaseJune 25, 2023 – N° 14 Fabrice Brégier is appointed Chairmanof SCOR’s Board of Directors SCOR’s Board of Directors, which met on June 25, 2023, has unanimously decided to appoint Fabrice Brégier non-executive Chairman, with immediate effect. This decision was made on the unanimous recommendation of the Nomination Committee, at the conclusion of a demanding and rigorous succession process initiated in spring 2022. Over the months since the process began, the Nomination Committee, assisted by the international recruitment firm Egon Zehnder, has met on numerous occasions to define the search criteria for the future Chairman, to select first-rate individuals who could match the expected profile, and finally to meet the candidates most likely to take the helm of the Board. The Committee, chaired by Adrien Couret, ultimately...

Continue reading

Press Release: ALTUVIIIO late-breaking data at ISTH demonstrates highly effective bleed protection in children with severe hemophilia A with once-weekly dosing

Press Release: ALTUVIIIO late-breaking data at ISTH demonstrates highly effective bleed protection in children with severe hemophilia A with once-weekly dosing

Written by Customer Service on . Posted in Public Companies.

  ALTUVIIIOTM late-breaking data at ISTH demonstrates highly effective bleed protection in children with severe hemophilia A with once-weekly dosing XTEND-Kids data confirm the efficacy and safety profile of ALTUVIIIO with simple, weekly 50 IU/kg dosing for both adults and children ALTUVIIIO’s expanding evidence of a first and best-in-class profile supports Sanofi’s commitment to delivering paradigm shifting therapies for Rare Diseases Paris, June 25, 2023. Pivotal data from the Phase 3 XTEND-Kids study evaluating ALTUVIIIOTM [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein] once-weekly prophylaxis, a first-in-class, high-sustained factor VIII replacement therapy, in previously treated patients younger than 12 years of age with severe hemophilia A were presented today in a late-breaking session at the Annual Meeting of...

Continue reading

MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa

MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa

Written by Customer Service on . Posted in Public Companies.

MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa First placebo-controlled randomized trial in HS to report positive topline results using HiSCR75 as the primary endpoint Primary endpoint HiSCR75 met with 29 percentage points (ppt) delta vs placebo (p=0.0002) at week 12, setting a new bar in HS HiSCR50 met with 38 ppt delta vs placebo (p

Continue reading

Communiqué vidéo de Patrick MARCHE et Bernard VOISIN

Communiqué vidéo de Patrick MARCHE et Bernard VOISIN

Written by Customer Service on . Posted in Public Companies.

                                                          Communiqué vidéo de Patrick MARCHE et Bernard VOISIN NEOLIFE® (Euronext Growth : FR0011636083 – ALNLF), (la « Société ») annonce partager un communiqué vidéo de Patrick MARCHE et Bernard VOISIN, respectivement Président du Conseil de Surveillance et Président du Directoire de la Société. Communiqué vidéo Patrick MARCHE et Bernard VOISIN La Société rappelle toujours se tenir à disposition des actionnaires via l’adresse mail investors@neolife.fr pour répondre à leurs questions en amont de l’assemblée générale du 26 juin. CONTACTNEOLIFE®investors@neolife.fr Attachment CP NEOLIFE 25 JUIN 2023 – Vidéo Direction

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.